Recent studies demonstrated that inhibition of GSK3 by celecoxib promoted the degradation of c-FLIP and death receptor-induced apoptosis, suggesting that GSK3 might stabilize c-FLIP and antagonize tumor resistance to TRAIL [12]. This evidence concerns the gene CFLAR and neoplasm.